期刊文献+

Reduction of Glucose Metabolism in Olfactory Bulb is an Earlier Alzheimer's Disease-related Biomarker in 5XFAD Mice 被引量:1

Reduction of Glucose Metabolism in Olfactory Bulb is an Earlier Alzheimer's Disease-related Biomarker in 5XFAD Mice
原文传递
导出
摘要 Background:Early diagnosis assumes a vital role in an effective treatment of Alzheimer's disease (AD).Most of the current studies can only make anAD diagnosis after the manifestation of typical clinical symptoms.The present study aimed to investigate typical and other biomarkers of AD to find a possible early biomarker.Methods:A total of 14 5XFAD mice (at 3 and 6 months old),with 14 age-matched wild-type (WT) mice as control,were enrolled in this case-control study.Morris water maze test was performed to evaluate the cognitive function;buried food pellet test and olfactory maze test were employed to investigate the olfactory function;immunofluorescence to detect amyloid deposition and positron emission tomography to examine 2-deoxy-2-(18F) fluoro-D-glucose ([18F]-FDG) uptake in the hippocampus and cerebral cortex.Results:With the increasing age,cognitive performance (P =0.0262) and olfactory function were significantly deteriorated (day 1 P =0.0012,day 2 P =0.0031,day 3 P =0.0160,respectively) and the (18F)-FDG uptake was markedly decreased in multi-cerebral regions including the olfactory bulb (P 〈 0.0001),hippocampus (P =0.0121),and cerebral cortex (P 〈 0.0001).Of note,in 3-month-old 5XFAD mice,a significant decline of (18F)-FDG uptake in the olfactory bulb was found when compared with that of age-matched WT mice (P =0.023) while no significant difference was present when the uptakes in other cerebral regions were compared.Conclusions:The decline of (18F)-FDG uptake in the olfactory bulb occurs earlier than other incidents,serving as an earlier in vivo biological marker of AD in 5XFAD mice and making early diagnosis of AD possibly. Background:Early diagnosis assumes a vital role in an effective treatment of Alzheimer's disease (AD).Most of the current studies can only make anAD diagnosis after the manifestation of typical clinical symptoms.The present study aimed to investigate typical and other biomarkers of AD to find a possible early biomarker.Methods:A total of 14 5XFAD mice (at 3 and 6 months old),with 14 age-matched wild-type (WT) mice as control,were enrolled in this case-control study.Morris water maze test was performed to evaluate the cognitive function;buried food pellet test and olfactory maze test were employed to investigate the olfactory function;immunofluorescence to detect amyloid deposition and positron emission tomography to examine 2-deoxy-2-(18F) fluoro-D-glucose ([18F]-FDG) uptake in the hippocampus and cerebral cortex.Results:With the increasing age,cognitive performance (P =0.0262) and olfactory function were significantly deteriorated (day 1 P =0.0012,day 2 P =0.0031,day 3 P =0.0160,respectively) and the (18F)-FDG uptake was markedly decreased in multi-cerebral regions including the olfactory bulb (P 〈 0.0001),hippocampus (P =0.0121),and cerebral cortex (P 〈 0.0001).Of note,in 3-month-old 5XFAD mice,a significant decline of (18F)-FDG uptake in the olfactory bulb was found when compared with that of age-matched WT mice (P =0.023) while no significant difference was present when the uptakes in other cerebral regions were compared.Conclusions:The decline of (18F)-FDG uptake in the olfactory bulb occurs earlier than other incidents,serving as an earlier in vivo biological marker of AD in 5XFAD mice and making early diagnosis of AD possibly.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2015年第16期2220-2227,共8页 中华医学杂志(英文版)
基金 grants from the National Natural Science Foundation of China (No. 81171216 and No. 91232709), and the Key Clinical Specialty Discipline Construction Program of Fujian and Nation, China.
关键词 Alzheimer's Disease BIOMARKER 2-deoxy-2-(18F) Fluoro-D-glucose Olfactory Bulb Positron EmissionTomography-computed Tomography Alzheimer's Disease Biomarker 2-deoxy-2-(18F) Fluoro-D-glucose Olfactory Bulb Positron EmissionTomography-computed Tomography
  • 相关文献

参考文献37

  • 1Ferri CP,Prince M,Brayne C,Brodaty H,Fratiglioni L,Ganguli M,et al.Global prevalence of dementia:A Delphi consensus study.Lancet 2005;366:2112-7.
  • 2Ballard C,Gauthier S,Corbett A,Brayne C,Aarsland D,Jones E.Alzheimer's disease.Lancet 2011;377:1019-31.
  • 3Birks J,Harvey RJ.Donepezil for dementia due to Alzheimer's disease.Cochrane Database Syst Rev 2006;32:158-63.
  • 4Richarz U,Gaudig M,Rettig K,Schauble B.Galantamine treatment in outpatients with mild Alzheimer's disease.Acta Neurol Scand 2014;129:382-92.
  • 5Thakker DR,Weatherspoon MR,Harrison J,Keene TE,Lane DS,Kaemmerer WF,et al.Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice.Proc Natl Acad Sci U S A 2009;106:4501-6.
  • 6Green RC,Schneider LS,Amato DA,Beelen AP,Wilcock G,Swabb EA,et al.Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease:A randomized controlled trial.JAMA 2009;302:2557-64.
  • 7Aisen PS,Gauthier S,Vellas B,Briand R,Saumier D,Laurin J,et al.Alzhemed:A potential treatment for Alzheimer's disease.Curt Alzheimer Res 2007;4:473-8.
  • 8Leroy K,Ando K,Héraud C,Yilmaz Z,Authelet M,Boeynaems JM,et al.Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.J Alzheimers Dis 2010;19:705-19.
  • 9Albers MW,Tabert MH,Devanand DE Olfactory dysfunction as a predictor of neurodegenerative disease.Curr Neurol Neurosci Rep 2006;6:379-86.
  • 10Murphy C.Loss of olfactory function in dementing disease.Physiol Behav 1999;66:177-82.

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部